Company intelligence / Profile preview
Biosimilar Solutions
Napa, California, USAbiosimilarsolutions.com ↗
- Ownership
- Private
- Employees
- ~350
- Development stage
- Phase 3
01
Overview
The company has developed multiple biosimilars including versions of Neupogen, Neulasta, Aranesp, Humira, Forteo, and Herceptin. They planned to launch Neupogen and Neulasta biosimilars from Puerto Rico, with production slated to begin in 2022. They also have a COVID-19 virus-like particle vaccine candidate that eliminates cold chain requirements.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Recombinant proteinsmonoclonal antibodiesbiosimilarsCOVID-19 vaccine (virus-like particle)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Reliance Life SciencesOcyonBio
Beyond the preview
Go deeper on Biosimilar Solutions.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biosimilar Solutions.